Pfizer/BioNTech first dose 85% effective after 2-4 weeks — study

Pfizer/BioNTech first dose 85% effective after 2-4 weeks — study

Friday, February 19, 2021

Print this page Email A Friend!


JERUSALEM (AFP) — The first dose of the Pfizer/BioNTech vaccination is 85 per cent effective against coronavirus infection between two and four weeks after inoculation, according to astudypublished in the Lancet medical journal.

The survey was carried out on healthcare workers at the largest hospital in Israel, which on December 19 launched a mass vaccination campaign regarded as the world's fastest.

Israeli studies have found the vaccine developed by US pharma giant Pfizer and its German partner BioNTech to be 95 per cent effective one week after a second jab, while the Lancet report focused on more than 9,000 medical staff at Sheba hospital near Tel Aviv.

Some 7,000 of them received the first dose and the rest were not inoculated.

From the group, 170 were diagnosed with COVID-19 after tests carried out only on those showing symptoms or who had been in contact with coronavirus carriers.

Fifty-two per cent of them were found to have not been vaccinated.

Comparing the two groups, the Shebastudycalculated that the vaccine was 47 per cent effective between one and 14 days after inoculation, rising to 85 per cent after 15 to 28 days.

"What we see is a really high effectiveness already right after two weeks, between two weeks to four weeks after vaccine, already high effectiveness of 85 per cent reduction of symptomatic infection," Gili Regev-Yochay, co-author of thestudy, told a small group of journalists.

He said that despite the vaccine being "amazingly effective", scientists are still studying whether fully vaccinated people can transmit the virus to others.

"That is the big, big, question. We are working on it. This is not on this paper and I hope we will have some good news soon," said Regev-Yochay.

Israel has delivered a shot of the Pfizer/BioNTech vaccine to 4.23 million residents, or 47 per cent of its nine million population, 2.85 million of whom have received the recommended full course of two jabs, latest health ministry figures show.

Separately on Friday, Pfizer and BioNTech said their vaccine can stand warmer temperatures than initially thought, potentially simplifying the jab's complex cold-chain logistics.

The companies said they have asked the US Food and Drug Administration to allow for the vaccine to be stored for up to two weeks at minus 25 to minus 15 degrees Celsius (minus 13 to five degrees Fahrenheit) — temperatures commonly found in pharmaceutical freezers and refrigerators.

Under the existing guidelines, the Pfizer/BioNTech jab needs to be stored at a frigid minus 80 to minus 60 C until five days before use, a delicate process that requires special ultra-cold containers for shipping and dry ice for storage.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT